Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
Susan Galbraith, Executive Vice President Oncology Haematology R&D at AstraZeneca, shared on LinkedIn:
”It’s been a great few days at ASH25, and I am very proud that AstraZeneca had its largest presence to date, reflecting our haematology research strategy in action.
We shared scientific updates on our T‑cell engager research targeting CD19 and on cell therapy approaches, including our investigational BCMAxCD19 CAR‑T programme.
These efforts are focused on better understanding immune‑based approaches in blood cancers and coming away from ASH I’m encouraged by the science and collaboration I saw in action as we work to advance the next wave of blood cancer care.
For a closer look at some of these scientific developments, Anas Younes the latest article provides more detail.”
All from ASH25 featured in Hemostasis Today.
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC
-
May 11, 2026, 16:34Jane Hankins: Excited to Have Been a Part of the Faculty of ASH CRTI LA
-
May 11, 2026, 16:28Conan McIlwrath at the Rare Bleeding Disorders Conference Representing The Haemophilia Society as Chair
-
May 11, 2026, 16:24Anna A. Avagyan: Presenting Armenia’s Experience at SIOP Europe 2026
-
May 11, 2026, 16:18Mohamed Elkhider: Raising Awareness on Aortic Dissection
-
May 11, 2026, 16:11David McIntosh: A Pensioner’s Reflections on Blood Donation